SLC4A4 is a novel driver of enzalutamide resistance in prostate cancer
Cancer Letters · 2024-08 · 597 · 217070
DOI: 10.1016/j.canlet.2024.217070 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2024-08. Verfasst von Hao-Jie Chen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Shanghai Children's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200062, China; Department of Urolog…. Hauptthemen laut MEDLINE: Benzamides, Drug Resistance, Neoplasm, Nitriles, Phenylthiohydantoin. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
The androgen receptor signaling inhibitor (ARSI) enzalutamide (Enz) has shown critical efficacy in the treatment of advanced prostate cancer (PCa). However, the development of drug resistance is a significant factor contributing to mortality in PCa patients. We aimed to explore the key mechanisms of Enz-resistance. Through analysis of GEO databases, we identified SLC4A4 as a novel driver in Enz resistance. Long-term Enz treatment leads to the up-regulation of SLC4A4, which in turn mediates P53 lactylation via the NF-κB/STAT3/SLC4A4 axis, ultimately leading to the development of Enz resistance and progression of PCa. SLC4A4 knockdown overcomes Enz resistance both in vitro and in vivo. Hence, our results suggest that targeting SLC4A4 could be a promising therapeutic strategy for Enz resistance. STATEMENT OF SIGNIFICANCE: SLC4A4 is a novel driver of enzalutamide resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Shanghai Children's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200062, China; Department of Urology, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University,…
- Department of Ultrasound in Medicine, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200233, China.
- Department of Urology, Shanghai Children's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200062, China.
- Department of Urology, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200092, China.
- Department of Urology, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200092, China. Electronic address: yuyongjiang@xinhuamed.com.cn.
- Department of Urology, Shanghai Children's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200062, China. Electronic address: drhuangyichen@163.com.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Chen, H. J., Yu, M. M., Huang, J. C., Lan, F. Y., Liao, H. H., Xu, Z. H., Yu, Y. J., Huang, Y. C., & Chen, F. (2024). SLC4A4 is a novel driver of enzalutamide resistance in prostate cancer. Cancer Letters, 597, 217070. https://doi.org/10.1016/j.canlet.2024.217070
Vancouver
Chen HJ, Yu MM, Huang JC, Lan FY, Liao HH, Xu ZH, et al. SLC4A4 is a novel driver of enzalutamide resistance in prostate cancer. Cancer Letters. 2024;597:217070. doi:10.1016/j.canlet.2024.217070
BibTeX
@article{Chen2024,
author = {Chen, Hao-Jie and Yu, Ming-Ming and Huang, Jia-Cheng and Lan, Fu-Ying and Liao, Hai-Hong and Xu, Zi-Han and Yu, Yong-Jiang and Huang, Yi-Chen and Chen, Fang},
title = {SLC4A4 is a novel driver of enzalutamide resistance in prostate cancer},
journal = {Cancer Letters},
year = {2024},
volume = {597},
pages = {217070},
doi = {10.1016/j.canlet.2024.217070}
}
EUVIMED